Argan (AGX) has opened Q1 2027 with total revenue of US$291.0 million and basic EPS of US$3.30, against trailing twelve month revenue of US$1.0 billion and EPS of US$11.64 that came with 61.1% year over year earnings growth. Over the last year, the company has seen revenue move from US$874.2 million to US$1.0 billion on a trailing basis, while EPS stepped up from US$6.35 to US$11.64, pointing to a higher earnings contribution on each dollar of sales. With net margins running stronger than a year ago, this latest quarter keeps the focus squarely on how durable that profitability profile really is for investors.

See our full analysis for Argan.

With the headline numbers on the table, the next step is to set these results against the most widely held market narratives about Argan and see which stories match the data and which start to look stretched.

61.1% earnings growth reshapes profit mix

• Over the last 12 months, net income reached US$161.3 million on US$1.0 billion of revenue, with net margin at 15.5% compared with 11% a year earlier, alongside 61.1% year over year earnings growth.
• Supporters of the bullish view point to this combination of 61.1% trailing earnings growth and a 15.5% net margin as backing multi year growth potential, yet
  • bullish analysts are assuming revenue will grow 27.1% per year and margins rise from 14.6% to 15.8%, while the data here cites revenue growth expectations of 15.1% per year and earnings growth around 13% per year, which is a more moderate pace.
  • the bullish case also leans on a large project backlog and recent high Power segment margins, but the reported margins are described as lumpy, so the recent 15.5% net margin may not reflect a smooth trend.

Bulls arguing that Argan's backlog and recent margin strength could support higher long term earnings may want to see how those assumptions stack up against project level details and forecasts in the full bull case breakdown 🐂 Argan Bull Case

Q1 2027 profit level versus recent quarters

• Q1 2027 net income of US$46.1 million and basic EPS of US$3.30 sit below Q4 2026 net income of US$49.2 million and basic EPS of US$3.54, while revenue in Q1 2027 of US$291.0 million is above Q4 2026 revenue of US$262.1 million.
• Bears arguing that recent profitability is hard to sustain will notice that
  • Q1 2027 net income of US$46.1 million compares with US$30.7 million in Q3 2026 and US$22.6 million in Q1 2026, so the last few quarters all sit above the earlier period that fed into the five year compound earnings growth rate of 35.6% per year.
  • even with a step down from Q4 2026 net income of US$49.2 million, the trailing 12 month net income of US$161.3 million is higher than the US$100.1 million level a year earlier, which is the backdrop for both bullish and bearish narratives stressing how sensitive earnings could be to execution on a relatively small number of large projects.

Skeptics who think recent profitability might prove fragile can see how those concerns are laid out against the numbers in the bear case breakdown 🐻 Argan Bear Case

Rich P/E and DCF gap stand out

• The stock trades on a trailing P/E of 60.4x compared with a peer average of 32.1x and a US Construction industry average of 48.7x, and the current share price of US$694.72 sits above a DCF fair value of about US$251.01.
• Consensus narrative comments that investors are paying up for strong growth and backlog, yet
  • earnings are forecast to grow about 13% per year, which is below the 16.2% per year earnings growth rate cited for the broader US market, so the 60.4x P/E multiple is not paired with faster than market earnings growth in this dataset.
  • the gap between the US$694.72 share price and the US$251.01 DCF fair value underlines why valuation is flagged as a key risk even after a period of 61.1% earnings growth and a 15.5% trailing net margin.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Argan on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of strong earnings and valuation questions leaves you uncertain, take a closer look at the underlying data and form your own view with 2 key rewards and 2 important warning signs

See What Else Is Out There

Argan's rich 60.4x P/E and share price far above the cited DCF fair value highlight valuation as a key vulnerability despite recent strong earnings.

If paying a premium for growth that is not forecast to outpace the wider US market feels uncomfortably stretched, compare that setup with companies screened as 49 high quality undervalued stocks

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.